The shares will commence trading May 12, 2006, on the NASDAQ National Market under the symbol BMTI. BioMimetic Therapeutics, Inc. has granted the underwriters a 30-day option to purchase an additional 690,000 shares of its common stock to cover over-allotments, if any. Deutsche Bank Securities Inc. will be acting as the sole book-running manager of this offering, Pacific Growth Equities, LLC will be acting as the co-lead manager and First Albany Capital, Inc. and AG Edwards & Sons, Inc will be co-managers.

BioMimetic Therapeutics, Inc. is developing and commercializing bio-active drug-device combination products for the healing of musculoskeletal injuries and disease, including periodontal, orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. The Company's product and product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration.

BioMimetic is a former SEBIO Investor Forum presenter.